| Ticker: | RZLT |
| Current Price: | $3.66 |
| % Daily Change: | -5.56% |
| Volume (1,000s): | 5,728.61 |
| Average Volume (1,000s): | 1,887.21 |
| Market Cap (M): | $353.54 |
| 1/2/2024 Price: | $1.02 |
| Change Since Inception: | 260.59% |
Rezolute, Inc.
275 Shoreline Drive
Suite 500
Redwood City, CA 94065
United States
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Our antibody therapy, RZ358 (ersodetug), is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital hyperinsulinism (cHI) and tumor hyperinsulinism (tHI).
We are caregivers, loved ones, and patients. The spectrum of our humanity informs and inspires everything that we do in our mission to develop therapies that will make a difference.
-Nevan Charles Elam, Founder & CEO